CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
We are very excited to launch our new website! Please take a few moments to click around and explore...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...